01712nas a2200265   4500000000100000008004100001653002300042653001200065653000800077653002500085653001500110100001400125700002400139700003500163700002100198700002000219700001800239700001500257700002000272245008900292856009100381300000900472490000700481520095800488       2023                            d10arheumatic diseases10aleprosy10aSLE10arheumatoid arthritis10atratamento1 aCruz V. A1 ade Albuquerque C. P1 aResende Guimarães M. F. B. de1 aDionello C. da F1 aRibeiro S. L. E1 ade Souza V. A1 aGomes C. M1 ada Mota L. M. H00aNew insights at the interface between leprosy and immune-mediated rheumatic diseases  uhttps://www.frontiersin.org/articles/10.3389/fmed.2023.1239775/pdf?isPublishedV2=False  a1-120 v103 a<p>Leprosy is an infectious and contagious disease of slow evolution, triggered by&nbsp;<em>Mycobacterium leprae</em>. Arthritis is its third most common manifestation, after cutaneous and peripheral nerve involvement. Since musculoskeletal symptoms may be the initial presentation of the disease, it is important for health professionals to recognize its rheumatic manifestations for early diagnosis and appropriate treatment, especially in endemic areas. In addition, cases of leprosy have increased globally, notably in patients undergoing treatment with TNF-α blockers and due to the increase in migration and travel of people from developing countries to developed countries. This review proposes to discuss the main scenarios of mimicry of different rheumatic diseases by leprosy, as well as the role of immunosuppressive drugs used in rheumatology practice in the treatment of reactional states and in the risk of developing the infection.</p>